PEAK6 Investments LLC bought a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT – Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 4,409 shares of the company’s stock, valued at approximately $353,000.
A number of other hedge funds have also modified their holdings of the business. Essex Investment Management Co. LLC raised its position in shares of PROCEPT BioRobotics by 0.3% in the third quarter. Essex Investment Management Co. LLC now owns 80,992 shares of the company’s stock valued at $6,489,000 after buying an additional 228 shares during the last quarter. Values First Advisors Inc. acquired a new stake in PROCEPT BioRobotics during the third quarter worth about $27,000. Arizona State Retirement System increased its position in PROCEPT BioRobotics by 2.8% during the second quarter. Arizona State Retirement System now owns 12,840 shares of the company’s stock worth $784,000 after purchasing an additional 350 shares during the last quarter. KBC Group NV increased its position in PROCEPT BioRobotics by 32.6% during the third quarter. KBC Group NV now owns 1,531 shares of the company’s stock worth $123,000 after purchasing an additional 376 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in PROCEPT BioRobotics by 4.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,913 shares of the company’s stock worth $606,000 after purchasing an additional 408 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors and hedge funds.
PROCEPT BioRobotics Trading Up 3.1 %
Shares of PRCT stock opened at $99.45 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The firm has a market cap of $5.19 billion, a PE ratio of -51.00 and a beta of 0.99. The company has a 50-day moving average of $84.96 and a two-hundred day moving average of $74.34. PROCEPT BioRobotics Co. has a 1-year low of $36.52 and a 1-year high of $103.81.
Insider Activity
In other news, Director Antal Rohit Desai sold 44,867 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $80.11, for a total value of $3,594,295.37. Following the completion of the transaction, the director now owns 197,453 shares of the company’s stock, valued at approximately $15,817,959.83. This trade represents a 18.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Kevin Waters sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $82.51, for a total transaction of $2,062,750.00. Following the completion of the transaction, the chief financial officer now directly owns 96,096 shares of the company’s stock, valued at approximately $7,928,880.96. The trade was a 20.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 539,668 shares of company stock valued at $47,960,744. 17.40% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Several research firms recently issued reports on PRCT. Wells Fargo & Company restated an “overweight” rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday. Truist Financial restated a “buy” rating and set a $105.00 price objective (up from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. TD Cowen raised their price objective on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Jefferies Financial Group assumed coverage on shares of PROCEPT BioRobotics in a research report on Thursday, November 14th. They set a “hold” rating and a $95.00 price objective for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $75.00 target price on shares of PROCEPT BioRobotics in a research note on Tuesday, October 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, PROCEPT BioRobotics currently has an average rating of “Moderate Buy” and an average target price of $97.86.
Get Our Latest Stock Analysis on PROCEPT BioRobotics
PROCEPT BioRobotics Company Profile
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Read More
- Five stocks we like better than PROCEPT BioRobotics
- Options Trading – Understanding Strike Price
- Tesla Poised to Hit Record Highs This Holiday Season
- Pros And Cons Of Monthly Dividend Stocks
- The Salesforce Rally is Just Getting Started: Here’s Why
- Dividend Capture Strategy: What You Need to Know
- 3 Chip and Data Center Stocks That Can Keep Rising in 2025
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.